Tanja Badovinac-Črnjević

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

Ian E. Krop, Sung‐Bae Kim, Antonio González-Martı́n et al. · The Lancet Oncology · 2017 · 523 citations

Medicine, Oncology, Pharmacotherapy +17

Challenges to effective cancer control in China, India, and Russia

Paul E. Goss, Kathrin Strasser‐Weippl, Brittany Bychkovsky et al. · The Lancet Oncology · 2014 · 504 citations

Public Health, Health Policy, Oncology +12

Planning cancer control in Latin America and the Caribbean

Paul E. Goss, Brittany Lee, Tanja Badovinac-Črnjević et al. · The Lancet Oncology · 2013 · 504 citations · Full text

Public Health, Health Policy, Oncology +14

Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study

Dennis C. Sgroi, Judy‐Anne W. Chapman, Tanja Badovinac-Črnjević et al. · Breast Cancer Research · 2016 · 72 citations · Full text

Medicine, Oncology, Breast Oncology +15

Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial

Paul E. Goss, Dawn L. Hershman, Angela M. Cheung et al. · The Lancet Oncology · 2014 · 53 citations

Medicine, Oncology, Pharmacology +17